Cancer immunotherapy
DOI:
https://doi.org/10.37711/rpcs.2023.5.3.420Keywords:
cancer development, tumor immunity, antitumor response, immunotherapy, evasionAbstract
Immunotherapy as a treatment for cancer has developed considerably in recent years, proving to be a promising type of treatment against cancer. This therapy consists of the administration of substances produced by the body or through a laboratory, to help the immune system to accurately identify and eliminate neoplastic cells in the patient. The latest research proposes to improve the recognition of tumor antigens and to take advantage of the effector mechanisms of the individual's own immune cells; it also suggests directly stopping cancer cells, since they stimulate the immune system's capacity to recognize them by activating defense mechanisms that prevent cancer proliferation. However, it remains a challenge to increase effectiveness, specifcity and safety, as this type of treatment is not without limitations and adverse effects. Among the types of immunotherapy currently available are: administration of cytokines, vaccines, viruses, monoclonal antibodies, checkpoint inhibitors, and TIL and CAR-T cell therapy, all of which have as their main function to modulate the immune response. In the present literature review, important aspects of enhancing antitumor immunity and suppressing the mechanisms of immunosurveillance evasion, with their relationship to immunotherapy, will be presented.
Downloads
References
Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for year 2020: An overview. Int J Cancer [Internet]. [Consultado 2021 Abr 5] doi: 10.1002/ijc.33588
Organización Panamericana de la Salud. Enfermedades Transmisibles y Análisis de Salud/Información y Análisis de Salud. Situación de la salud en las Américas: indicadores básicos Washington, D.C. OPS; 2016 [Internet]. [Consultado 2016] Disponible en: http://iris.paho.org/xmlui/handle/123456789/31288
Romero Pineda MT. La inmunología contra el cáncer. La inmunología contra el cáncer [Internet]. 2020 [Consultado 2016 ene];110(110):1–110. Disponible en: https://www.npunto.es/revista/22/la-inmunologia-contra-el-cancer
Inmunoterapia para el cáncer [Internet]. Bethesda: Instituto Nacional del Cáncer; 2019 [Consultado 2023 Abr 27]. Disponible en: https://www.cancer.gov/espanol/cancer/tratamiento/tipos/inmunoterapia
Bermejo-Bescós P, Martín-Aragón S.(2019). Inmunoterapia y tratamiento oncológico. Una estrategia prometedora. Offarm, 30(5), 53–59. https://www.elsevier.es/es-revista-offarm-4-pdf-X0212047X1127661X
Reyes SJ, González KB, Rodríguez, C, Navarrete-Muñoz C, Salazar AP., Villagra A, et al. [Internet] 2020.
Cáncer immunotherapy: an update. Revista médica de Chile, 148(7), 970–982 doi: doi.org/10.4067/S0034-
Ortiz-Aguirre JP, Velandia-Vargas EA, Rodríguez-Bohorquez OM, Bernal-Estévez D, Parra-López CA. Inmunoterapia personalizada contra el cáncer basada en neoantígenos. Revisión de la literatura. Rev. Fac. Med. [Internet]. 2021 [Consultado 2023 abr 26]; 69(3):e81633. https://doi.org/10.15446revfacmed.v69n3.81633
Gale RP. Síntomas de cáncer. Manual MSD versión para público general [Internet]. 2022 Oct [Consultado 2023 may 8]. Disponible en: https://www.msdmanuals.com/es-ec/hogar/c%C3%A1ncer/introducci%C3%B3n-al-%C3%A1ncer/s%C3%ADntomas-de-c%C3%A1ncer
Abbott M, Ustoyev Y. Cancer and the Immune System: The History and Background of Immunotherapy. Semin Oncol Nurs. [Internet] 2019 [Consultado 2023 may 8];35(5):150923 doi: 10.1016/j.soncn.2019.08.002.
Vasquez L, Castro D, De León J, Beltrán B. Inmunoterapia en cáncer: de los inicios al premio Nobel. Rev Peru Med Exp Salud Publica. [Internet] 2020 [Consultado 2023 abr 19];37(1):115-21 doi: doi.org/10.17843/rpmesp.2020.371.4329
Sepúlveda CD, Puente PJ. Células natural killer y el sistema inmune innato en la patología infecciosa. Rev
Med Chil [Internet]. 2018;128(12) doi: doi.org/10.4067/s0034-98872000001200009
Raskov H, Orhan A, Christensen JP, Gögenur I. Cyotoxic CD8+ T cells in cancer and cancer immunotherapy. Br J Cáncer. 2021 Jan 19;124(2):359-67.
Baek AE. Immunogenic Lncs to cancer therapy. Sci Signal [Internet]. 2023 [Consultado 2023 mar 07];16(775) doi: doi.org/10.1126/scisignal.adh4085
Abbas AK, Lichtman AH, Pillai S. Inmunología celular y molecular. 10ª ed. Madrid: Elsevier España; 2020.
Philip M, Schietinger A. CD8+ T cell differentiation and dysfunction in cancer. Nat Rev Immunol [Internet].
[Consultado 2023 jun 21];22(4):209–23 doi: doi. org/10.1038/s41577-021-00574-3
de León J, Universidad de San Martín de Porres, Facultad de Medicina Humana, Instituto de investigaciones, Centro de Investigación de Infectología e Inmunología. Lima, Perú, Pareja A. Inmunología del cáncer I: bases moleculares y celulares de la respuesta inmune antitumoral. Horiz méd [Internet]. 2018 [Consultado 2023 jun 06];18(3):80–9 doi: doi.org/10.24265/horizmed.2018.v18n3.11
Wissinger E. CD8+ T Cells [Internet]. Immunology.org. [Internet]. 2018 [Consultado 2023 jun 06] Disponible en: https://www.immunology.org/sites/default/fles/2022-07/CD8%20T%20cells.pdf
Bonaventura P, Alcazer V, Mutez V, Tonon L, Martin J, Chuvin N, et al. Identifcation of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy. Sci Adv [Internet]. 2022 [Consultado 2023 jun 06] ;8(4) doi: doi.org/10.1126/sciadv.abj3671
Orhan A, Christensen JP, Gögenur I, Raskov H. Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. Br J Cancer. 2021 Jan 19;124(2):359-67.
Dhodapkar MV. Navigating the Fas lane to improved cellular therapy for cancer. J Clin Invest [Internet].
[Consultado 2023 jun 08];129(4):1522–3 doi: doi.org/10.1172/jci127581
Gallastegui C, Bernardez B, Regueira A, Dávila C, Leboreiro B. 2002. Inmunología. En Gamundi Planas MG, coordinadora. Farmacia Hospitalaria (Tomo II). Madrid: Sociedad Española de Farmacia Hospitalaria; 2002. p. 1077-1106.
Pio R, Ajona D, Ortiz-Espinosa S, Mantovani A, Lambris JD. Complementing the cancer-immunity cycle. Front Immunol [Internet]. 2019 [Consultado 2023 may 15]; 10:774. Doi: doi.org/10.3389/fmmu.2019.00774
Mendoza A, Yewdell WT, Hoyos B, Schizas M, Bou-Puerto R, Michaels AJ, et al. Assembly of a spatial circuit
of T-bet–expressing T and B lymphocytes is required for antiviral humoral immunity. Sci Immunol [Internet]. 2021 [Consultado 2023 abr 28]; 6(60) doi: doi.org/10.1126/sciimmunol.abi4710
Kirchhammer N, Trefny MP, Natoli M, Brücher D, Smith SN, Werner F, et al. NK cells with tissue-resident
traits shape response to immunotherapy by inducing adaptive antitumor immunity. Sci Transl Med [Internet]. 2022 [Consultado 2023 may 20]; 14(653) doi: doi.org/10.1126/scitranslmed.abm9043
Moreno Fernández ME, Rugeles López MT, Montoya Guarín CJ. Células NK: generalidades y papel durante
la infección por el virus de la VIH-I ATREIA [Internet]. 2020 [Consultado 2023 may 23];20(1):47–63. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0121-07932007000100006
Kaiser G. Microbiología (Kaiser) [Internet]. Libretexts; 2022 [Consultado 2023 may 23]. Disponible en: https://n9.cl/microbiology
Kent SJ, Navis M, Isitman G, Kramski M, Chung AW Center RJ, et al. Immune escape from HIV-specifc antibody-dependent cellular cytotoxicity (ADCC) pressure. Proc Natl Acad Sci U S A [Internet]. 2021 [Consultado 2023 may 23]; 108(18):7505–10 doi: doi.org/10.1073/pnas.1016048108
Huerta López JG, Cravioto Quintana P, Velázquez MP. Interacciones entre el cáncer y el sistema inmunológico [Internet]. 2018 [Consultado 2023 abr 27]. Disponible en: https://www.medigraphic.com/pdfs/alergia/al-2017/al172e.pdf
Chen S, Xing Z, Geng M, Zhao R, Yang X, Zhu X, et al. Macrophage fusion event as one prerequisite for inorganic nanoparticle-induced antitumor response. Sci Adv [Internet]. 2023 [Consultado 2023 abr 27]; 9(29)
doi: doi.org/10.1126/sciadv.add9871
Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat
Rev Drug Discov [Internet]. 2022 [Consultado 2023 may 23]; 21(11):799–820 doi: doi.org/10.1038/s41573-022-
-5
Pulgar Andrade AA, Carvallo Ruiz DE, Martínez Núñez EN. Mecanismos de evasión tumoral a la respuesta inmune. Cienc médica [Internet]. 2023 [Consultado 2023 may 23]; 25(2):157–67 doi: doi.org/10.51581/rccm.v25i2.514
Cornel AM, Mimpen IL, Nierkens S. MHC class I downregulation in cancer: Underlying mechanisms and potential targets for cancer immunotherapy. Cancers (Basel) [Internet]. 2020 [Consultado 2023 may 23]; 12(7):1760 doi: doi.org/10.3390/cancers12071760
Garrido F. MHC/HLA class I loss in cancer cells. Adv Exp Med Biol [Internet]. 2019 [Consultado 2023 jun 08];1151:15–78 doi: doi.org/10.1007/978-3-030-17864-2_2
Alspach E, Lussier DM, Miceli AP, Kizhvatov I, DuPage M, Luoma AM, et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature [Internet]. 2019 [Consultado 2023 may 15];5 74(7780):696– 701 doi: doi.org/10.1038/s41586-019-1671-8
Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev. Cancer [Internet]. 2019 [Consultado 2023 may 15];19(3):133–50 doi: doi.org/10.1038/s41568-019-0116-x
Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature [Internet]. 2018 [Consultado 2023 jun 08]; 541(7637):321–30 doi: doi.org/10.1038/nature21349
Clark RA. Kill shot: Flu vaccine is a stone cold cancer killer. Sci Immunol [Internet]. 2020 [Consultado 2023 jun 08]; 5(44) doi: doi.org/10.1126/sciimmunol.abb0239
Ferrarelli LK. Crafty evasion of antitumor immunity.Sci Signal [Internet]. 2021 [Consultado 2023 may 23];
(712) doi.org/10.1126/scisignal.abn5462
Vazquez T, Nehar-Belaid D, Florez L, Levacher B, Courau T, Brimaud F, et al. TGF-B and VEGF cooperatively control the immunotolerant tumor environment and the effcacy of cancer immunotherapies. JCI Insight [Internet]. 2018 [Consultado 2023 jun 08]; 1(9): e85974 doi:10.1172/jci.insight.85974
Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised,
controlled, phase 3 study. Lancet Oncol. 2019 [Consultado 2023 jun 23]; 20(9):1239-1251. doi: 10.1016/S1470-2045(19)30388-2
Reyes SJ, González KB, Rodríguez C, Navarrete-Muñoz C, Salazar AP, Villagra A, et al. Cancer immunotherapy: an update. Rev Med Chil [Internet]. 2020 [Consultado 2023 jun 23];148(7):970–82 doi: doi.org/10.4067/S0034-98872020000700970
Adamik J, Butterfeld LH. Whats next for cancer vaccines. Sci Transl Med [Internet]. 2022 [Consultado 2023
jun 23]; 14(670) doi: doi.org/10.1126/scitranslmed. abo4632
Machado-Alba JE. Los medicamentos de origen biotecnológico, el futuro comienza ahora. An Real Acad Farm [Internet]. 2019 [Consultado 2023 may 23];80, No 1:49–90. Disponible en: http://www.anales.ranf.com/2014/vol1/06_1462.htm
Daver NG. Inmunoterapia [Internet]. 2020 [Consultado 2023 may 26] Disponible en: https://www.lls.org/sites/default/fles/fle_assets/FS9S_SP_Immunotherapy2020.pdf
Carpena JG, Palazón JC, Blanes M. Revisión sistemática de los efectos adversos cutáneos causados por fármacos inhibidores de los puntos de control inmunitario: características, manejo y pronóstico. Actas Dermosifliogr [Internet]. 2022 [Consultado 2023 may 25]; 113(4):376–87 doi: doi.org/10.1016/j.ad.2021.09.005
Topalian SL, Taube JM, Pardoll DM. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science
[Internet]. 2020 [Consultado 2023 may 25]; 367(6477) doi: doi.org/10.1126/science.aax0182
Kono K. Current status of cancer immunotherapy. J Stem Cells Regen Med [Internet]. 2018 [Consultado 2023 may 25];10(1):8–13 doi: doi.org/10.46582/jsrm.1001003
Saint-Jean M, Knol A-C, Volteau C, Quéreux G, Peuvrel L, Brocard A, et al. Adoptive cell therapy with tumor-infltrating lymphocytes in advanced melanoma patients J Immunol Res [Internet]. 2018 [Consultado 2023 may 27]; 2018:1–10 doi: doi.org/10.1155/2018/3530148
Bommareddy PK, Shettigar M, Kaufman HL. Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol [Internet]. 2018 [Consultado 2023 may 27];18(8):498–513 doi: /doi.org/10.1038/s41577-018-0014-6
Wu K, Lyu F, Wu S-Y, Sharma S, Deshpande RP, Tyagi A, et al. Engineering an active immunotherapy for personalized cancer treatment and prevention of recurrence. Sci Adv [Internet]. 2022[Consultado 2023 jun 08] ;9(17) doi: doi.org/10.1126/sciadv.ade0625
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Tatiana Katherine Naranjo-Vela , Daniela Alexandra Rosero-Freire
This work is licensed under a Creative Commons Attribution 4.0 International License.
